A CLINICAL TRIAL TO CONFIRM THE EFFICACY OF OLAPARIB IN COMBINATION WITH BEVACIZUMAB, ADMINISTERED AS MAINTENANCE THERAPY AFTER A FRONTLINE PLATINUM BASED CHEMOTHERAPY PLUS BEVACIZUMAB, IN THE TREATMENT OF PATIENTS WITH OVARIAN TUMOURS SHOWING A GENETIC DEFECTS IN A DNA REPAIR MECHANISM CALLED HOMOLOGOUS RECOMBINATION (DEFINED AS HRD POSITIVE, WHERE HRD MEANS HOMOLOGOUS RECOMBINATION DEFICIENCY)

Category Primary study
Registry of TrialsClinical Trials Information System
Year 2022
This article has no abstract
Epistemonikos ID: e4b8bdccc63cce1e8d2570d6b0701eae39e0ddf4
First added on: Mar 21, 2025